Benzinga | May 5, 2021 04:48PM EDT

Regenxbio Q1 EPS $(1.20) Beats $(1.28) Estimate, Sales $18.90M Miss $23.23M Estimate

Regenxbio (NASDAQ:RGNX) reported quarterly losses of $(1.20) per share which beat the analyst consensus estimate of $(1.28) by 6.25 percent. This is a 11.11 percent decrease over losses of $(1.08) per share from the same period last year. The company reported quarterly sales of $18.90 million which missed the analyst consensus estimate of $23.23 million by 18.64 percent. This is a 7.12 percent increase over sales of $17.64 million the same period last year.